Lexicon Pharma (LXRX) Tops Q2 EPS by 4c

Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $12.36 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance